Silexion Therapeutics Is Building a Tumor-Targeting Technology That’s Aligned With Big Pharma’s Billion-Dollar Priorities (NASDAQ: SLXN)
NY (PinionNewswire) — Oncology dealmaking has roared back, with big pharma spending billions to acquire therapies that can hit multiple...





